Open an account

GRI Bio

GRI · NASDAQ

$1.46+$0.01 (+0.69%)TodayMarket closed ·
Prev close $1.45

About GRI

GRI Bio, Inc. engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. The company is headquartered in La Jolla, California and currently employs 4 full-time employees. The company went IPO on 2021-02-10. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The firm is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. The company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).

Employees
4
Headquarters
La Jolla, California
Listed
Feb 10, 2021
Sector
Health Care
Industry
Biotechnology
Website
gribio.com

GRI key statistics

Market cap
3.19M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
59.39K
Volume
46.90K
Open price
$1.45
High today
$1.54
Low today
$1.45
52 Week high
$64.12
52 Week low
$1.36

GRI Bio (GRI) at a glance

As of Oct 20, 2026, GRI Bio (GRI) shares are priced at $1.46, giving the company a market cap of 3.19M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.45 and $1.54. The current price is 0.7% above the day's low and 5.0% below its high.

Volume so far is 46.90K shares, below the average of 59.39K shares a day.

Over the past year GRI Bio has ranged from $1.36 to $64.12, and now sits 0% of the way up that range.

GRI Bio met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.91 per share against an estimate of -$1.21.

The average analyst price target is $156.57, 10624.0% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $156.57
Low
$27.27
Now
$1.46
High
$294.00

GRI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 33.6% on average.

  1. Q3 FY24: reported -$318.92 per share against an estimate of -$350.95
  2. Q4 FY24: reported -$0.56 per share against an estimate of -$153.84
  3. Q1 FY25: reported -$162.40 per share against an estimate of -$116.23
  4. Q2 FY25: reported -$36.68 per share against an estimate of -$37.05
  5. Q3 FY25: reported -$35.84 per share against an estimate of -$26.30
  6. Q4 FY25: reported -$116.61 per share against an estimate of -$29.55
  7. Q1 FY26: reported -$1.61 per share against an estimate of -$0.9141
  8. Q2 FY26: reported -$0.91 per share against an estimate of -$1.21

GRI news

  • UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To Buy

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Vandana Singh

    GRI Bio Drug Shows Promising Lung Function Recovery In Patients With Thickened Lungs

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Crude Oil Falls 1%; Meta Earnings Top Views

  • Avi Kapoor

    Nasdaq Surges Over 1%; Microsoft Posts Upbeat Earnings

  • 12 Health Care Stocks Moving In Monday's Intraday Session

Similar companies

Companies in the same industry as GRI Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.